Document Detail


Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
MedLine Citation:
PMID:  20528149     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lung metastases are the main cause of death in patients with osteosarcoma (OS). Salvage chemotherapy has been largely unsuccessful in improving the long-term survival of these patients. Understanding the mechanisms that play a role in the metastatic process may identify new therapeutic strategies. We have demonstrated that the cell surface Fas expression, the Fas/FasL signaling pathway, and the constitutive expression of FasL in the lung microenvironment play a critical role in the metastatic potential of OS cells. Here we review the status of Fas expression in two sets of OS cells, human SAOS and LM7 and murine K7 and K7M2, which differ in their ability to metastasize to the lungs. We demonstrated that Fas expression inversely correlated with metastatic potential. Evaluation of Fas expression in a set of lung metastases from patients demonstrated low or no Fas expression consistent with our hypothesis that Fas+ osteosarcoma cells cannot form metastases. The absence of FasL in the lung allows Fas+ osteosarcoma cells to form metastases indicating that the microenvironment is an important contributor to the metastatic potential of osteosarcoma cells. Disruption of the signal transduction pathway using Fas-associated death domain dominant negative (FDN) also allowed Fas+ cells to form lung metastases. Aerosol Gemcitabine (GCB) upregulated Fas expression and induced tumor regression in wild-type Balb/c mice but not Fas L-deficient mice. In conclusion, Fas constitutes an early defense mechanism that allows Fas+ tumor cells to undergo apoptosis when in contact with constitutive FasL in the lung. Fas- cells or cells with a corrupted Fas pathway evade this defense mechanism and form lung metastases. The aerosol delivery of chemotherapeutic agents that upregulate Fas expression may benefit patients with established pulmonary metastases.
Authors:
Nancy Gordon; Eugenie S Kleinerman
Related Documents :
18569169 - Involvement of fas signalling in 7beta-hydroxycholesterol-and cholesterol-5beta,6beta-e...
15632129 - Hsp72 inhibits fas-mediated apoptosis upstream of the mitochondria in type ii cells.
15295649 - Inhibiting apoptosis of ctll-2 cells to enhance their gvl effects via anti-fas ribozyme.
11828289 - Induction of apoptosis in malignant pleural mesothelioma cells by activation of the fas...
15350969 - Neonatal mice lacking functional fas death receptors are resistant to hypoxic-ischemic ...
15834099 - Corneal graft rejection occurs despite fas ligand expression and apoptosis of infiltrat...
23770239 - The transcription factor irf3 triggers "defensive suicide" necrosis in response to vira...
12543039 - Macrophages and post-burn immune dysfunction.
18514159 - The role of chemokines in controlling granulomatous inflammation in schistosoma mansoni...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Journal of aerosol medicine and pulmonary drug delivery     Volume:  23     ISSN:  1941-2703     ISO Abbreviation:  J Aerosol Med Pulm Drug Deliv     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-10     Completed Date:  2010-12-02     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101475057     Medline TA:  J Aerosol Med Pulm Drug Deliv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  189-96     Citation Subset:  T    
Affiliation:
Children's Cancer Hospital, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aerosols
Animals
Antigens, CD95 / physiology*
Antimetabolites, Antineoplastic / administration & dosage,  therapeutic use*
Bone Neoplasms / drug therapy*,  pathology
Deoxycytidine / administration & dosage,  analogs & derivatives*,  therapeutic use
Fas Ligand Protein / physiology*
Humans
Lung Neoplasms / drug therapy*,  secondary
Mice
Mice, Inbred BALB C
Osteosarcoma / drug therapy*,  secondary
Grant Support
ID/Acronym/Agency:
CA16672/CA/NCI NIH HHS; CA42992/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Aerosols; 0/Antigens, CD95; 0/Antimetabolites, Antineoplastic; 0/Fas Ligand Protein; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro aerosol deposition in the oropharyngeal region for Staccato loxapine.
Next Document:  Near Full-Length Genomic Characterization of a Novel HIV Type 1 Subtype B/C Recombinant Strain from ...